CervoMed (CRVO) Current Assets (2010 - 2026)
CervoMed (CRVO) posted Current Assets of $15.1 million for Q1 2026, down 33.94% sequentially from $22.9 million in Q4 2025, and down 60.82% YoY from $38.6 million in Q1 2025.
CervoMed (CRVO) Current Assets (2010 - 2026) Analysis & Trends
CervoMed has reported Current Assets for 17 years, with the latest figure at $15.1 million in Q1 2026.
- Quarterly Current Assets fell 60.82% year-over-year to $15.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (down 60.82% YoY) and the FY2025 annual result came in at $22.9 million, down 46.89% from the prior year.
- Current Assets declined to $15.1 million in Q1 2026 per CRVO's latest filing, from $22.9 million in the prior quarter.
- Over five years, Current Assets peaked at $48.8 million in Q3 2024 and troughed at $4.2 million in Q4 2022.
- A 5-year average of $26.6 million and a median of $27.8 million in 2022 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2025: Current Assets tumbled 89.01% in 2022, then jumped 384.31% in 2025.
- Over 5 years, Current Assets stood at $4.2 million in 2022, then surged by 139.67% to $10.0 million in 2023, then soared by 332.34% to $43.1 million in 2024, then tumbled by 46.89% to $22.9 million in 2025, then plunged by 33.94% to $15.1 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $15.1 million, $22.9 million, and $30.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | CervoMed | 27.05 Mn | 27.05 Mn | - | 25.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.99 Mn |
| Mar 31, 2026 | 15.11 Mn |
| Dec 31, 2025 | 22.88 Mn |
| Sep 30, 2025 | 30.61 Mn |
| Jun 30, 2025 | 38.08 Mn |
| Mar 31, 2025 | 38.58 Mn |
| Dec 31, 2024 | 43.08 Mn |
| Sep 30, 2024 | 48.81 Mn |
| Jun 30, 2024 | 47.33 Mn |
| Mar 31, 2024 | 7.97 Mn |
| Dec 31, 2023 | 9.96 Mn |
| Sep 30, 2023 | 11.84 Mn |
| Mar 31, 2023 | 18.40 Mn |
| Dec 31, 2022 | 4.16 Mn |
| Sep 30, 2022 | 26.32 Mn |
| Jun 30, 2022 | 29.18 Mn |
| Mar 31, 2022 | 33.57 Mn |
| Dec 31, 2021 | 37.82 Mn |
| Sep 30, 2021 | 40.72 Mn |
| Jun 30, 2021 | 43.86 Mn |